Copaxone 40 mg/mL Glatiramer Acetate – 12 Pre-filled Pens

Copaxone 40 mg/mL Pen contains glatiramer acetate, an immunomodulating prescription medicine used in Türkiye to reduce the frequency of attacks in ambulatory adults with relapsing-remitting multiple sclerosis (RRMS). The Turkish 40 mg/mL pack contains 12 ready-to-use pens. One 40 mg dose is injected under the skin three times each week, with at least 48 hours between doses, only under the supervision of a neurologist or an MS-experienced doctor.

Copaxone 40 mg/mL Pen at a glance

What is Copaxone 40 mg/mL?

Copaxone is a disease-modifying medicine for multiple sclerosis. Glatiramer acetate is a mixture of synthetic polypeptides made from four naturally occurring amino acids. Its exact therapeutic mechanism is not fully understood. Current evidence suggests that it modifies immune activity involving monocytes, dendritic cells, B cells, and adaptive T-cell responses rather than acting as a general immune suppressant.

The product is not a painkiller, steroid, rescue medicine, or cure for MS. It is used over time to lower relapse activity in the population covered by the local authorization. It does not treat an acute relapse immediately and it should not be started, stopped, or switched without the treating neurologist.

Who may be prescribed Copaxone 40 mg?

The current Turkish product information describes use in ambulatory patients with relapsing-remitting multiple sclerosis who have experienced at least two neurological attacks with full or partial recovery during the previous two years. The exact eligibility decision depends on diagnosis, disease activity, MRI findings, prior therapy, pregnancy plans, comorbidities, and the neurologist’s assessment.

Product indications can differ between markets. The United States label uses the broader term “relapsing forms of MS,” while Turkish and several European product documents use more specific wording and state that Copaxone is not indicated for primary or secondary progressive MS. This page follows the Turkish pack and Turkish product context.

How to use Copaxone 40 mg/mL Pen

1. Use one pre-filled 40 mg/mL pen subcutaneously three times each week.
2. Keep a minimum of 48 hours between doses. A fixed schedule such as Monday, Wednesday, and Friday may help, but follow the days prescribed for you.
3. Before the first self-injection, receive hands-on training from a doctor or nurse. The first administration should be supervised and the patient observed for 30 minutes afterward.
4. Inspect the pen and solution. Do not use a damaged, leaking, expired, frozen, cloudy, discoloured, or particle-containing product.
5. Choose a permitted subcutaneous site such as the abdomen, upper arm, hip, or thigh. Avoid injured, painful, lumpy, hardened, inflamed, or discoloured skin.
6. Rotate the site with every injection. Repeated injection into the same area increases the risk of persistent lipoatrophy and skin injury.
7. Use each pen once only. Do not share it, mix its contents with another medicine, or reuse the device.
8. Place the used pen immediately in a puncture-resistant sharps container and follow local disposal instructions.

Nine essential Copaxone safety checks

1. Confirm the exact strength

Copaxone 40 mg/mL is a three-times-weekly product. It must not be confused with a 20 mg/mL daily schedule. Never convert or alternate between strengths without a new clinician-approved plan.

2. Keep doses at least 48 hours apart

Injecting doses too close together increases medication-error risk. If a dose is missed, do not double the next dose. Contact the prescriber or pharmacist for an individualized restart schedule.

3. Screen for allergy

Do not use Copaxone if you are allergic to glatiramer acetate, mannitol, or another listed component. Anaphylaxis may resemble an immediate post-injection reaction, so urgent symptoms must never be dismissed as “normal.”

4. Recognize immediate post-injection reactions

Flushing, chest pain, shortness of breath, palpitations, or a rapid heartbeat can begin within minutes. Many episodes are brief and resolve without treatment, but severe, persistent, recurrent, or allergy-type symptoms require immediate medical assessment.

5. Rotate injection sites

Redness, pain, itching, swelling, inflammation, and a small lump can occur locally. Systematic rotation helps reduce irritation and localized loss of fatty tissue. Never inject into an area already showing lipoatrophy or necrosis.

6. Review liver, kidney, and heart history

Tell the clinician about current or previous liver disease, alcohol-related liver problems, kidney impairment, or heart disease. Glatiramer acetate has not been specifically studied in renal impairment, and rare liver injury—including severe cases—has been reported.

7. Review pregnancy and breastfeeding plans

Discuss pregnancy, planned pregnancy, or breastfeeding with the neurologist before use. Do not stop effective MS therapy suddenly because of a positive pregnancy test; obtain individualized advice promptly.

8. Check every other medicine and supplement

Provide a current list of prescription medicines, non-prescription products, vitamins, and herbal supplements. No food interaction is expected because Copaxone is injected, but the complete treatment plan still needs professional review.

9. Protect the cold chain

Keep unopened pens in the original outer carton in a refrigerator at 2–8°C. Do not freeze. If refrigeration is temporarily unavailable, the Turkish information allows storage below 25°C for a single period of up to one month; record the date and follow the leaflet and pharmacist’s instructions. Never use a pen that has frozen.

When to obtain urgent medical help

Call emergency services for breathing difficulty, wheezing, throat tightness, swelling of the face, lips, tongue, or throat, widespread hives, collapse, severe dizziness, or fainting. Seek prompt medical advice for jaundice, dark urine, marked fatigue, persistent nausea, severe abdominal pain, an unusually painful injection site, tissue breakdown, or symptoms that do not settle.

Common side effects

Injection-site reactions are the most frequently reported effects. Other reported effects can include headache, anxiety, nausea, rash, chest pain, flushing, palpitations, back pain, weakness, and infections. The full list is much longer and frequency varies by formulation and study. Read the patient leaflet supplied with the exact Turkish pack and report suspected adverse effects through the healthcare professional or the local pharmacovigilance route.

Monitoring and follow-up

There is no single blood test that proves Copaxone is working. Follow-up generally combines relapse history, neurological examination, tolerability, adherence, and MRI assessment. Liver or other laboratory testing may be ordered when clinically indicated. Keep a record of injection days, sites, missed doses, immediate reactions, and any skin change so the treatment team can review patterns accurately.

Frequently asked questions

Can Copaxone 40 mgcure multiple sclerosis?

No. It is a disease-modifying treatment intended to reduce relapse activity; it does not cure MS or reverse every existing symptom.

Can I use the Copaxone 40 mg pen every day?

No. The 40 mg/mL schedule is three times weekly with at least 48 hours between injections. A daily glatiramer schedule uses a different strength and must not be substituted.

Should the pen warm to room temperature?

The Turkish patient instructions advise taking one pen out and allowing about 20 minutes to reach room temperature naturally. Do not microwave it, place it in hot water, leave it in direct sunlight, or use another heating method.

Does the pack contain 12 pens?

Yes. The current Teva Türkiye product catalogue lists a commercial pack of 12 units for Copaxone 40 mg/mL.

Verified references and responsible purchase

Information was checked against the official Teva Türkiye product page and the updated Copaxone 40 mg/mL professional information. Pack appearance and local wording can change; always treat the physical carton and leaflet supplied with the medicine as the final reference.

Copaxone requires a valid prescription, reliable cold-chain handling, and a legitimate pharmacy supply route. Explore related categories in autoimmune disease treatments. This guide supports—but does not replace—the prescribing neurologist, pharmacist, or emergency service.